- Study: Whooping cough vaccine may not prevent infection
- FDA requests label and packaging changes for certain topical antiseptic products
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.
The agency announced the approval of Optimer Pharmaceuticals’ Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea, also known as CDAD.
Clostridium difficile can cause diarrhea and lead to colitis, as well as other serious intestinal diseases and, in severe cases, death. The bacteria are spread by people touching items or surfaces contaminated with the bacteria or spores and then touching their mouths.